Olivia Tyrrell

Baker & McKenzie LLP


Olivia Tyrrell is a partner in the Corporate and Securities Practice Group in Chicago. Ms. Tyrrell has also practiced in the Firm's Sydney and Barcelona offices and gained extensive experience in counseling clients on a wide variety of corporate and securities transactions. She is a member of Baker McKenzie's North America Pharmaceuticals & Healthcare Steering Committee, the American Bar Association's Task Force on International Transactions and the Chicago Council on Foreign Relations. Additionally, she acts as board member and treasurer of Kaleidoscope Inc., and is also a volunteer for Lawyers in the Classroom at McCutcheon Elementary. Ms.Tyrrell received the “Chicago 40 Under 40” award from The National Law Journal.

Practice Focus

Ms. Tyrrell advises clients on a broad range of corporate transactions, particularly on cross-border mergers, acquisitions, joint ventures, strategic alliances, corporate reorganizations and co-development and licensing agreements. She has acted as lead counsel for several multinational pharmaceutical and healthcare companies in high-profile transactions. Ms. Tyrrell has also worked on several large and complex transactions in India. In addition, she routinely advises clients on establishing operations outside the United States.

Representative Legal Matters

  • Advised Abbott Laboratories with respect to a wide range of transactions, including:
    • The sale to Mylan of a portfolio of branded specialty and generic drugs in developed markets outside the United States (USD5.3 billion);
    • Spin-off of Abbott Laboratories’ research-based pharmaceutical business;
    • Global separation and spin-off of its research-based pharmaceutical business and the formation of a new publicly-traded biopharmaceutical company, AbbVie Inc.
    • Acquisition of Piramal Healthcare Limited’s Healthcare Solutions business (USD3.8 billion);
    • Acquisition of Solvay’s pharmaceutical, vaccine and diagnostics businesses (USD6.2 billion);
    • Acquisition of Guidant’s worldwide vascular interventions and endovascular solutions businesses in 35 jurisdictions (USD4.6 billion);
    • Acquisition of the cardiology, radiology and peripheral interventional business of Jomed N.V. in 22 jurisdictions;
    • License and Supply Agreement with Zydus Cadila of India for 24 Zydus pharmaceutical products in 15 emerging markets (and option for 40 additional products).
  • Advised Hospira, Inc. with respect to its acquisition of India’s Orchid Chemicals & Pharmaceuticals generic injectable pharmaceuticals business (USD400 million) and its acquisition of Mayne Pharma Inc., an Australian publicly traded company with operations in 32 countries (USD2.1 billion).
  • Advised Schering-Plough Corporation in connection with its acquisition of Organon BioSciences from Akzo Nobel (USD14.4 billion).
  • Advised CommScope, Inc. with respect to the international aspects of the cash merger/going private transaction with The Carlyle Group (approximately USD3 billion), its merger with Andrew Corporation (approximately USD1.7billion) and its acquisition of Avaya's Connectivity Solution Business (approximately USD260 million).
    • Professional Associations and Memberships

      • Law Society of Queensland - Member
      • American Bar Association - Member
      • Chicago Bar Association - Member
      • Chicago Council on Foreign Relations - Member
      • Illinois State Bar Association - Member


      • Illinois~United States (2004)
      • Queensland~Australia (2001)


      • Loyola University Chicago School of Law (J.D.) (2003)
      • Queensland University of Technology (LL.B. summa cum laude) (2001)
      • Queensland Institute of Technology (Bachelor of Business Accounting summa cum laude, University Medalist) (1998)


      • English

      Previous Offices

      • Sydney